Alunbrig® (brigatinib) – Expanded indication
May 22, 2020 - Takeda announced the FDA approval of Alunbrig (brigatinib), for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
Download PDF
